CN116036174A - Medicine for treating pulmonary nodules and preparation method thereof - Google Patents
Medicine for treating pulmonary nodules and preparation method thereof Download PDFInfo
- Publication number
- CN116036174A CN116036174A CN202310206788.0A CN202310206788A CN116036174A CN 116036174 A CN116036174 A CN 116036174A CN 202310206788 A CN202310206788 A CN 202310206788A CN 116036174 A CN116036174 A CN 116036174A
- Authority
- CN
- China
- Prior art keywords
- treating pulmonary
- pulmonary nodules
- medicine
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 59
- 230000002685 pulmonary effect Effects 0.000 title claims abstract description 44
- 229940079593 drug Drugs 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title abstract description 22
- 241000255789 Bombyx mori Species 0.000 claims abstract description 22
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 14
- 238000009835 boiling Methods 0.000 claims abstract description 13
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 12
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- 238000002791 soaking Methods 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 11
- 206010056342 Pulmonary mass Diseases 0.000 claims description 7
- 235000021028 berry Nutrition 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 5
- 241000255791 Bombyx Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 239000000203 mixture Substances 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 235000019640 taste Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000003908 quality control method Methods 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 description 21
- 241000700159 Rattus Species 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 8
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000931143 Gleditsia sinensis Species 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000024121 nodulation Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000723345 Chrysophyllum Species 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000221785 Erysiphales Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037391 Pulmonary granuloma Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000033687 granuloma formation Effects 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Botany (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine preparations, and discloses a medicine for treating pulmonary nodules and a preparation method thereof. The components comprise: the preparation method comprises the steps of adding distilled water which is eight times of the total weight into stiff silkworm, schisandra chinensis, golden boiling grass and spina gleditsiae, soaking for 30 minutes, then controlling the temperature to be 60-100 ℃ for decoction for 1-3 times, each time for 1-3 hours, then filtering out the decoction, concentrating and drying, and obtaining dry paste, namely the medicine for treating pulmonary nodules. The traditional Chinese medicine composition for treating pulmonary nodules provided by the invention has the advantages of less traditional Chinese medicine taste, low cost and small toxic and side effects. The preparation process is simple to operate, quality control is easy to carry out in the production process, and the prepared traditional Chinese medicine composition is stable in chemical components.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and in particular relates to a medicine for treating pulmonary nodules and a preparation method thereof.
Background
Modern medical research has shown that pulmonary sarcoidosis is a systemic disease characterized by non-cheese granulomatous inflammation of epithelial cells of unknown cause, whose key mechanisms of occurrence are cellular and humoral immune responses of the organism caused by unknown antigens. With the increasing technological level and biotechnology, recent studies have shown that metabolic dysfunction is an important contributor to pulmonary nodules. The lung of a human body is an important respiratory and immune organ, when the metabolic function of the human body is damaged, the metabolic abnormality of the microcirculation function of the human body is caused by the processes of generation, differentiation, migration, aggregation and the like of various immune cells, so that inflammatory reaction and pulmonary granuloma formation or fibrosis are caused, and the improper treatment can induce canceration and even death.
With the rapid development of cities, the living and working pressures of a plurality of people living in large cities are continuously increased, and along with the gradual highlighting of the contradiction of environmental problems, the related diseases in the aspect of lungs, especially lung nodules, are induced, and the increasing of the incidence rate year by year plays a serious role in the stabilization of families and the peace of society; the treatment of patients with early pulmonary nodules in modern medical clinic is mostly glucocorticoid medicines (methotrexate and the like), and the patients with early pulmonary nodules can have a certain treatment effect, but can easily cause serious cerebrovascular diseases and abnormal reactions of endocrine metabolism even endanger life after being taken for a long time. The traditional Chinese medicine has the characteristics of low price, small toxic and side effects and long-term effective curative effect in the aspect of treating diseases, and particularly has unique advantages in treating early stage nodular symptoms of lung cancer lesions.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides a medicine for treating pulmonary nodules and a preparation method thereof, wherein the medicine is prepared by compatibility and combination of stiff silkworm, golden-boiling grass, shizandra berry and spina gleditsiae, can be taken for a long time from the aspects of resolving phlegm and resolving masses, dispelling wind and dredging collaterals, tonifying qi and nourishing yin, and has small side effect and stable medicine effect.
The above object of the present invention is achieved by the following technical solutions: a medicament for treating pulmonary nodules, comprising the following components: bombyx Batryticatus, fructus Schisandrae chinensis, herba Pogostemonis, and spina Gleditsiae.
Further, the medicine components for treating pulmonary nodule comprise 5-10g of stiff silkworm, 2-6g of schisandra chinensis, 3-10g of spina gleditsiae and 5-10g of golden boiling grass.
The invention further preferably comprises the following components in proportion of stiff silkworm, golden-boiling grass, chinese magnoliavine fruit and spina gleditsiae=3:2:1:2.
A method for preparing a medicament for treating pulmonary nodules, comprising the following steps: adding distilled water which is eight times of the total weight into stiff silkworm, shizandra berry, golden boiling grass and spina gleditsiae, soaking for 30 minutes, then controlling the temperature to be 60-100 ℃ for decoction for 1-3 times, wherein each time of decoction lasts for 1-3 hours, then filtering out the decocted liquid medicine, concentrating and drying, and obtaining dry paste which is the medicine for treating lung nodules.
Further, the medicine for treating the pulmonary nodules is granules, tablets, pills and capsules.
In a further preferred method of the present invention, the preparation method of the medicine for treating pulmonary nodules comprises the steps of extracting for 3 times at a temperature of 80 ℃ for 3 hours each time.
The stiff silkworm is a traditional liver-pacifying wind-extinguishing drug, and can resolve phlegm and dissipate nodulation, calm wind and stop spasm, dispel wind and relieve pain. The flavor is pungent and salty, and can dispel wind, resolve phlegm, dredge collaterals, soften hardness and dissipate nodulation, and also can resolve phlegm. Modern researches have found that the stiff silkworm mainly contains protein and fat, and the powdery mildew on the body surface contains substances such as ammonium oxalate and the like, so that the stiff silkworm has strong blood sugar and blood pressure reducing effects. Modern pharmacological researches show that the stiff silkworm has a strong anticoagulation effect and a good antibacterial effect on bacterial infections such as staphylococcus aureus, pseudomonas aeruginosa and the like. In recent years, researches show that the stiff silkworm has better effect in inhibiting liver cancer cells and lung cancer cells.
The herba Hedyotidis Diffusae is the aerial part of Inulae flos, and has similar efficacy and taste to Inulae flos, but herba Hedyotidis Diffusae is preferred for dispelling phlegm. The modern clinic is mainly applied to the treatment of chronic bronchitis, upper respiratory tract infection, rheumatic arthritis, urinary tract infection and other diseases. Pharmacological studies show that the herba zedoariae has strong inhibition effect on herpesvirus.
Spina Gleditsiae is thorn of Gleditsia sinensis, and has similar effect as Chinese medicinal Gleditsia sinensis. Pungent and warm nature, entering liver and kidney meridians, has the actions of relieving swelling and expelling pus, promoting qi circulation and regulating qi, warming and activating meridians, and activating blood and removing blood stasis. The Chinese medicine is used for treating sore and ulcer, milk obstruction, and other diseases. Modern pharmacological studies show that the gleditsia sinensis stings can promote the secretion of respiratory mucosa and has good phlegm-resolving effect.
Fructus Schisandrae is the mature fruit of Schisandra chinensis of Magnoliaceae, has sour and astringent taste, is sweet and warm and moist, has lung qi astringing upwards, and nourishes kidney yin downwards, and is an essential drug for treating cough and asthma due to deficiency of long-term. Modern scientific researches show that schisandra chinensis has excitation effects on both nervous system and central system and also on respiratory system. Can also reduce blood pressure, blood lipid and serum transaminase level, and protect liver cells; enhancing cellular immunity, promoting the elevation of SOD level of viscera, and improving immunity, resisting oxidation and aging.
Compared with the prior art, the invention has the beneficial effects that: the component of the traditional Chinese medicine composition for treating pulmonary nodules, namely stiff silkworm, is monarch drug, spina gleditsiae and golden-boiling grass are ministerial drugs, and shizandra berry is adjuvant drug. Wherein, the stiff silkworm is used for resolving phlegm, resolving masses and dredging collaterals; spina gleditsiae is used for promoting qi circulation, regulating qi, detumescence, expelling pus, promoting blood circulation and removing blood stasis; the herba inulae is used for reducing qi and resolving phlegm and dispersing and promoting the circulation of water; the shizandra berry is added for astringing lung qi, nourishing kidney yin, tonifying qi, promoting the production of body fluid, calming heart and tranquilizing mind. The components act together to achieve the effect of treating pulmonary nodules. The traditional Chinese medicine composition for treating pulmonary nodules provided by the invention has the advantages of less traditional Chinese medicine taste, low cost and small toxic and side effects. The preparation process is simple to operate, quality control is easy to carry out in the production process, and the prepared traditional Chinese medicine composition is stable in chemical components. Pharmacological research experiment results show that the traditional Chinese medicine composition prepared by the extraction process provided by the invention can obviously reduce the expression level of serum TNF-alpha, IL-10, IL-6 and IL-1 beta, improve the pulmonary nodule swelling degree, and has the effects of improving the immune function and relieving pulmonary nodule lesions. The traditional Chinese medicine composition provided by the invention has reliable curative effect, and can be used for preparing medicines for treating pulmonary nodules.
Drawings
The invention will be further described with reference to the drawings and the detailed description
FIG. 1 is a schematic diagram showing the relationship between the drug components and the pulmonary nodule swelling inhibition ratio, wherein A is the relationship between the herba inulae, the schisandra chinensis and the pulmonary nodule swelling inhibition ratio; b is the relation between the swelling inhibition rate of the stiff silkworm, the golden-leaf grass and the pulmonary nodule; c is the relation between the swelling inhibition rate of stiff silkworm, spina gleditsiae and pulmonary nodule; d is the relation between the swelling inhibition rate of stiff silkworm, schisandra chinensis and pulmonary nodules; e is the relation between the herba inulae, spina gleditsiae and the swelling inhibition rate of the pulmonary nodules; f is the relation between the swelling inhibition rate of the schisandra chinensis, spina gleditsiae and the pulmonary nodule.
Detailed Description
The present invention is described in detail below by way of specific examples, but the scope of the present invention is not limited thereto. Unless otherwise specified, the experimental methods used in the present invention are all conventional methods, and all experimental equipment, materials, reagents, etc. used can be obtained from commercial sources.
Example 1
The traditional Chinese medicine raw materials of stiff silkworm, golden-boiling grass, schisandra chinensis and spina gleditsiae are in a ratio of (3:2:1:2); determining preparation process range by single factor experiment with extract rate as investigation index, adding 8 times of distilled water into Chinese medicinal materials, soaking for 0.5 hr, decocting for 1-3 times, each time for 1-3 hr, controlling temperature at 60-100deg.C, and using orthogonal experiment L 9 (3 4 ) Determining the optimal preparation process of the formula.
Table 1 table of the preparation process factor level
Table 2 results of the formulation preparation process test
Table 3 visual analysis results of the formulation preparation process:
table 4 formulation preparation process yields analysis of variance results of paste rate:
the test result can be obtained through visual analysis, when the paste yield (%) is taken as an observation index, the factor B has a remarkable influence on the preparation process, and the influence primary and secondary distribution of each factor through comparison and investigation is as follows: c > B > A > D, i.e. the times of decoction > the time of decoction > the temperature of decoction. Comprehensively considering the factors such as the contribution rate of each factor to extraction, energy loss, process and the like, the optimal preparation process combination is A 2 B 3 C 3 I.e. the decoction temperature of 80 ℃ is controlled, and the extraction is carried out for 3 times and 3 hours each time.
Example 2
1. Experimental animals:
186 SD male rats
2. Experimental period:
for 60 days
3. Instrument and reagent:
balance, silica suspension
4. Experimental drugs:
adding 8 times of distilled water into the raw materials, soaking for 0.5h, decocting for 3 times, each time for 3 hours, controlling the temperature at 80 ℃, mixing decoctions, filtering while hot, removing filter residues, concentrating the filter residues into 1g/mL of the contained medicine, and preparing into a medicine solution with stomach filling volume.
5. The molding method comprises the following steps:
the rats of each group were intraperitoneally injected with 3.0% sodium pentobarbital solution (dose: 45mg/kg body mass) and fixed after anesthesia. The rat neck skin was sterilized with 75.0% ethanol by volume, cut along the median cervical line, and the muscle was blunt-separated to expose its trachea. 200 mu L of a silica suspension with the mass concentration of 250g/L is injected into the trachea at one time by using non-exposed trachea cannula to pollute the stomach.
6. Detecting the index:
lung swelling coefficient = wet lung weight (g)/body weight (g) ×100%
Pulmonary nodule swelling inhibition = (dosing group pulmonary swelling system-blank group pulmonary swelling coefficient)/(model group pulmonary swelling coefficient-blank group pulmonary swelling coefficient) ×100%
7. Star point design experiment:
based on the preparation process experiment, the star point design with 4 factors and 3 levels is carried out by taking the dosage of stiff silkworm, golden-boiling grass, shizandra berry and Chinese honeylocust spine as investigation factors (represented by A, B, C, D) and taking the lung nodule swelling inhibition rate as an effect, and the factor level design is shown in the table.
TABLE 5 Star Point design factor level Table
8. The experimental method comprises the following steps:
the 186 SD rats are divided into blank groups and model groups by 6 SD rats, the blank groups are normally fed, the model groups are subjected to model building according to the method, the rats are randomly divided into model groups and star point design 1-29 administration groups after model building, the administration groups are given with drug solutions of different compatibility combinations every day, and the blank and model groups are given with equal amounts of physiological saline every day for 60 days. After the end of the administration, the rats of each group were sacrificed after anesthesia, the lung tissue weight of the rats was weighed, and the lung swelling coefficient and the lung nodule swelling inhibition ratio were calculated.
TABLE 6 Lung swelling coefficient of rats in blank and model groups
n＝6)
Table 7 experimental design and index determination:
table 8 analysis of variance and regression model coefficient significance test:
statistical analysis is carried out on the data by using Design-Expert 13.0 software, multi-element nonlinear regression fitting is carried out by taking the lung nodule swelling inhibition rate as an index, a polynomial model recommended by the software is adopted, and model term P is less than 0.05, so that a regression equation can be obtained: y=78.92+5.84a+5.50b+4.78c+7.65d-3.85 AB-3.53AC-0.45AD-0.325bc+8.47bd-6.33cd+2.44a 2 －7.34B 2 －6.41C 2 －1.87D 2 (R 2 = 0.8097), which indicates that the regression model fits well. The response surface and contour plot of the relationship between the factors and the inhibition rate of pulmonary nodule swelling are shown in the accompanying description (FIG. 1). The compatibility and combination of the software recommended prescription are stiff silkworm, golden-boiling grass, chinese magnoliavine fruit and spina gleditsiae=3:2:1:3.
Comparative example 1
The traditional Chinese medicine composition formula (lung clearing and stasis dissipating pill) for treating lung nodules is examined, and the comparison experiment is compared with the traditional Chinese medicine formula in the invention, and the traditional Chinese medicine composition formula is specifically as follows:
1. experimental animals:
SD male rats 40
2. Experimental period:
for 60 days
3. Instrument and reagent:
ELISA kit for TNF-alpha (tumor necrosis factor alpha), IL-10 (interleukin 10), IL-6 (interleukin 6) and IL-1 beta (interleukin 1 beta)
4. Experimental drugs:
the traditional Chinese medicine formula is prepared by adding 8 times of distilled water into stiff silkworm, golden-boiling grass, chinese magnoliavine fruit and spina gleditsiae=3:2:1:3, soaking for 0.5h, decocting at 80 ℃ for 3 times, decocting for 3 hours each time, mixing decoctions, filtering while the decoctions are hot, removing filter residues, concentrating the filter residues into 1g/mL of an internal medicine, and preparing a medicine solution with stomach filling volume.
The lung-heat clearing and stasis resolving pill (Hainanlong Santa Clara, 3g×6/box) is prepared into a 1g/mL drug suspension according to the preparation method of the traditional preparation.
5. The molding method comprises the following steps:
the rats of each group were intraperitoneally injected with 3.0% sodium pentobarbital solution (dose: 45mg/kg body mass) and fixed after anesthesia. The rat neck skin was sterilized with 75.0% ethanol by volume, cut along the median cervical line, and the muscle was blunt-separated to expose its trachea. 200 mu L of a silica suspension with the mass concentration of 250g/L is injected into the trachea at one time by using non-exposed trachea cannula to pollute the stomach.
6. Detecting the index:
serum TNF-alpha, IL-10, IL-6, IL-1 beta
7. The experimental method comprises the following steps:
the 40 SD rats are divided into a blank group, a model group, a comparison group (lung clearing and stagnation eliminating pills) and a preferred group (the invention) by 10 SD rats, wherein the blank group is normally fed, and the other 3 SD rats are subjected to modeling according to the method; after molding, the comparison group and the preferred group were administered 1mL/100g of the corresponding drug solution daily, and the blank and model groups were administered an equivalent amount of physiological saline daily for 60 days. After the end of the administration, the rats were anesthetized and sacrificed after the abdominal aorta was bled. Standing whole blood at room temperature for 30min, centrifuging at 4deg.C at 3500r/min for 10min, collecting supernatant, and detecting the contents of TNF- α, IL-10, IL-6 and IL-1β in serum by ELISA method.
TABLE 9 determination of the content of TNF-alpha, IL-10, IL-6 and IL-1 beta in rat serum
Comparing with blank group, P < 0.01; compared with the model group, the # P is less than 0.05, the # P is less than 0.01
As can be seen from Table 9, the levels of TNF- α, IL-10, IL-6, IL-1β were significantly increased in the model group (P < 0.01) compared to the blank group; compared with the model group, the serum TNF-alpha, IL-10, IL-6 and IL-1 beta content of the comparison group and the preferred group are obviously reduced (P is less than 0.01), and the serum immune factor level of the preferred group is closer to that of the blank group, and the effect is slightly better than that of the comparison group.
The above-described embodiments are only preferred embodiments of the invention, and not all embodiments of the invention are possible. Any obvious modifications thereof, which would be apparent to those skilled in the art without departing from the principles and spirit of the present invention, should be considered to be included within the scope of the appended claims.
Claims (6)
1. A medicament for treating pulmonary nodules, comprising the following components: bombyx Batryticatus, fructus Schisandrae chinensis, herba Pogostemonis, and spina Gleditsiae.
2. The medicine for treating pulmonary nodules according to claim 1, wherein the medicine components for treating pulmonary nodules comprise 5-10g of stiff silkworm, 2-6g of schisandra chinensis, 3-10g of spina gleditsiae and 5-10g of golden boiling grass.
3. The medicine for treating pulmonary nodules according to claim 1, wherein the medicine for treating pulmonary nodules comprises the components of stiff silkworm, golden-boiling grass, shizandra berry and spina gleditsiae=3:2:1:2.
4. The drug for treating pulmonary nodules of claim 1, wherein the drug for treating pulmonary nodules is in the form of a granule, tablet, pill, capsule.
5. A method for preparing a medicament for treating pulmonary nodules, comprising the steps of: adding distilled water which is eight times of the total weight into stiff silkworm, shizandra berry, golden boiling grass and spina gleditsiae, soaking for 30 minutes, then controlling the temperature to be 60-100 ℃ for decoction for 1-3 times, wherein each time of decoction lasts for 1-3 hours, then filtering out the decocted liquid medicine, concentrating and drying, and obtaining dry paste which is the medicine for treating lung nodules.
6. The method for preparing a medicine for treating pulmonary nodules according to claim 5, wherein the medicine for treating pulmonary nodules is prepared by decocting at 80 ℃ for 3 times and 3 hours each time.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310206788.0A CN116036174B (en) | 2023-03-07 | 2023-03-07 | Medicine for treating pulmonary nodules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310206788.0A CN116036174B (en) | 2023-03-07 | 2023-03-07 | Medicine for treating pulmonary nodules and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116036174A true CN116036174A (en) | 2023-05-02 |
| CN116036174B CN116036174B (en) | 2024-05-31 |
Family
ID=86133296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310206788.0A Active CN116036174B (en) | 2023-03-07 | 2023-03-07 | Medicine for treating pulmonary nodules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116036174B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177298A (en) * | 2016-08-22 | 2016-12-07 | 陶荣芝 | Bombyx Batryticatus composition of medicine |
| CN110604791A (en) * | 2019-09-29 | 2019-12-24 | 杨振岭 | Traditional Chinese medicine formula for treating cancer and preparation method thereof |
| CN115381915A (en) * | 2022-02-16 | 2022-11-25 | 重庆市中医院 | Traditional Chinese medicine composition for treating phlegm-heat stasis type pulmonary nodules as well as preparation method and application thereof |
-
2023
- 2023-03-07 CN CN202310206788.0A patent/CN116036174B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177298A (en) * | 2016-08-22 | 2016-12-07 | 陶荣芝 | Bombyx Batryticatus composition of medicine |
| CN110604791A (en) * | 2019-09-29 | 2019-12-24 | 杨振岭 | Traditional Chinese medicine formula for treating cancer and preparation method thereof |
| CN115381915A (en) * | 2022-02-16 | 2022-11-25 | 重庆市中医院 | Traditional Chinese medicine composition for treating phlegm-heat stasis type pulmonary nodules as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 原庆: "僵蚕能治疗肺结节吗", pages 1, Retrieved from the Internet <URL:https://www.bohe.cn/iask/view/eu3x2o2jckfw4n9.html> * |
| 我爱看匮伤: "武维屏教授，治疗肺结节10大方法，花1分钟看看", pages 1, Retrieved from the Internet <URL:http://www.360doc.com/content/21/0810/08/59016420_990369337.shtml> * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116036174B (en) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108310124B (en) | Lung heat clearing oral liquid for treating infantile cough and preparation method thereof | |
| CN116036174B (en) | Medicine for treating pulmonary nodules and preparation method thereof | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| CN102106999B (en) | A kind of compound Chinese medicinal preparation for the treatment of dysphagia after apoplexy and preparation method thereof | |
| CN101152379A (en) | Traditional Chinese medicine for treating cough and technique of preparing the same | |
| CN102671036B (en) | Traditional Chinese medicine oral liquid for treating chronic lung abscess and preparing method thereof | |
| CN101607032B (en) | Compound medicament for treating children cough and preparation method thereof | |
| CN116211993B (en) | Composition for treating senile chronic disease and its preparation method | |
| CN111494534A (en) | Traditional Chinese medicine composition for treating breast nodules and preparation method thereof | |
| CN112168947A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| NL2037306B1 (en) | A nutritional product for clearing and protecting the lungs and a preparation method thereof | |
| CN112741892B (en) | Traditional Chinese medicine composition for preventing and treating poultry myoglandular gastritis, oral liquid and preparation method | |
| CN115006466B (en) | Traditional Chinese medicine preparation for treating eczema with damp-heat and yang deficiency and preparation method thereof | |
| CN115607596B (en) | Health wine with uric acid reducing effect and preparation method thereof | |
| CN115212247B (en) | Preparation of nitraria tangutorum bobr and application thereof | |
| CN110025685B (en) | A liquid preparation containing propolis composition | |
| CN108938749B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN109091633B (en) | Composition for treating recurrent respiratory tract infection of children and preparation method and application thereof | |
| CN108578602B (en) | Traditional Chinese medicine composition for treating leukorrheal diseases and preparation method thereof | |
| CN106692698B (en) | Bletilla striata cough relieving granule and preparation method thereof | |
| CN105194545B (en) | A kind of Chinese medicine composition for treating asthma | |
| CN118121652A (en) | Plant essential oil formula for treating rhinitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |